siRNA Design: General Parameters
Proper design is a critical consideration for siRNA-mediated silencing. Two basic siRNA schemes have been successfully employed. The first strategy uses two 21 nucleotide RNAs, typically with a twonucleotide overhang at each 3′ end, that mimic the natural product of Dicer cleavage ( Figure 1 ). The second approach, referred to as short hairpin RNAs, or shRNAs ( Figure 1 ), uses sense and antisense sequences connected by a hairpin loop. RNA duplexes slightly longer than 21 nucleotides in length can also be used as these may be further processed intracellularly into 21-25 base siRNAs. Both siRNAs and shRNAs can be chemically synthesized and introduced into cells or expressed endogenously from a promoter. For endogenous expression, RNA polymerase III (Pol III) promoters have been utilized for transcribing si-and shRNAs, since they can be engineered to initiate transcription with the first base of the si/shRNA and because Pol III terminates transcription within a short run of 4-6 uridines (8,9) . RNA polymerase II promoters have also been successfully used (10) . RNAi has also been elicited by transfecting cells with pools of siRNAs generated by cleavage of in vitro transcribed long dsRNAs with recombinant Dicer or RNase III (11, 12) or with Escherichia coli RNase III (13) . Pooled siRNAs usually result in potent knockdown of target mRNA(s) while allowing discrimination between homologous sequences in gene families or alternatively spliced mRNAs. The choice of exogenously created siRNA or vector-delivered siRNA expression units will ultimately depend upon the application. Transfection of synthetic siRNAs provides only transient RNAi, but gives dose-response relationships that are easily controlled, making it more suitable for large-scale applications and multiplexing. On the other Figure 1 . Mechanism of siRNA-directed degradation of target mRNA in mammalian cells. shRNAs are processed to siRNAs, which have a two base 3′ overhang and recessed 5′ phosphate. The antisense strand of the siRNA (relative to the target) is incorporated into the RNA induced silencing complex (RISC). RISC is comprised of several proteins, at least one of which is an Argonaut family member in addition to an RNase. The siRNA directs targeted cleavage of the mRNA and the RISC complex can recycle. siRNA, small interfering RNA; shRNA, short hairpin RNA.
tify siRNA targets that produce desired effects at minimal (nanomolar) concentrations to minimize unintended effects and to design appropriate controls in siRNA knockdown experiments.
Target Sequence Selection
An siRNA's ability to stimulate degradation of its target RNA is heavily dependent on target sequence selection (3, 7, 12, 13, 21, 22) , but the reasons are not fully understood. Base composition (GC content) alone does not seem to be a factor (12) . More subtle structural aspects of the siRNA itself and of the target sequence, such as the ability to adopt the A-form helical structure (23) common to dsRNAs, may affect the efficiency of target site cleavage within the RISC complex. Studies utilizing methods to determine optimal in vivo ribozyme or antisense DNA target sites may be instructive. General RNA folding prediction software, such as mfold, do not reliably predict useful siRNA target sequences (see http://www.bioinfo. hand, stable, endogenous expression of si/shRNAs from integrating or episomal replicating vectors can cause longterm inhibition of gene expression-an important consideration for some therapeutic applications, such as the treatment of chronic viral infections.
Selectivity of RNAi
Some examples of siRNAs that are highly sequence-specific can be found in studies using RNAi in cancers that are associated with novel fusion transcripts. In chronic myeloid leukemia (CML), fusion bcr/abl transcripts are present in nearly all CML patients, as well as in 30% of adults with acute lymphoblastic leukemia (ALL). Transiently transfected siRNAs directed against the region spanning the bcr/abl fusion joint specifically reduced levels of the fusion bcr/abl transcripts and of the encoded p210 protein, without affecting the endogenous abl and bcr messages, despite the fact that parts of the siRNAs share perfect complementarity with these nonfusion transcripts (14, 15) . Importantly, the siRNA-induced reduction of the oncogenic transcript resulted in a desired physiological effect of cells becoming more susceptible to apoptosis. High selectivity will be required in therapeutic applications for which delivery to non-leukemic cells cannot be controlled. A cautionary note about selectivity comes from a study of Pol III expressed siRNAs targeting the fusion transcript characteristic of Ewing's sarcoma (16) . In this disease, the translocation t(11;22)(q24;q12) produces an oncogenic EWS/Fli-1 fusion protein detected in 85% of Ewing's sarcoma and primitive neuroectodermal tumor cells. Two different expressed siRNAs targeting sequences specific to the fusion were utilized. Both EWS/Fli-1 siRNAS specifically reduced the fusion mRNA relative to cellular β-actin. However, one of the siRNAs containing 17 bases of homology to Fli-1 partially reduced endogenous Fli-1 mRNA and also resulted in unanticipated N-myc down-regulation, highlighting the importance of monitoring cross-suppression of endogenous transcripts when using RNAi.
Off-Target Effects
There are conflicting reports about the potential "off-targeting" of siRNAs in mammalian cells. One study of siRNAs targeting a reporter construct (used in concert with DNA array analyses) showed no significant changes in the expression levels of nontargeted endogenous cellular genes (17) . In contrast, other investigations have demonstrated numerous off-target effects (18) (19) (20) . In one case, the off-target effects were concentration-dependent, with higher concentrations of siRNAs generating more off-targeting (20) . It is therefore important to iden-rpi.edu/~zukerm/seqanal/), but several commercial and academic web sites have useful algorithms for choosing siRNA target sequences. None of the in silico methods above takes into consideration the role of RNA chaperone proteins on inter-and intramolecular RNA interactions. A cell extract method that scans transcripts with inexpensive DNA oligonucleotides has proven to be useful for identifying ribozyme, antisense, and RNAi-susceptible target sequences (4, (18) (19) (20) . Another technique for identifying effective RNAi target sequences is to use a construct that includes the target gene of interest fused to a reporter, such as the enhanced green fluorescent protein (EGFP) (24) (Figure 2) . The siRNAdirected cleavage of the target gene sequence will result in loss of EGFP fluorescence, which can be quantitated. This approach has several advantages: (i) in vivo application, (ii) rapid readout, and (iii) effectiveness in standard tissue culture.
In an effort to rapidly and efficiently identify RNAi sensitive sequences in cells, we developed a PCR-based procedure for generating Pol III shRNA transcription units. The in vitro-amplified PCR products are transfected into mammalian cells containing the target mRNA (24) . A number of transcription units expressing different si/shRNAs targeting different sequences in the gene of interest can be rapidly synthesized and tested, since the transcriptional units are tagged with a 3′ sequence that allows easy PCR amplification from transfected cells, enabling researchers to test multiple shRNA sequences and isolate the most potent ones following cell sorting (24) .
Targeting Human Immunodeficiency Virus with RNAi
Human immunodeficiency virus (HIV) has become a prime target for RNAi due to problems with resistance to current drugs and the high cost of new drug development (25, 26) . Synthetic and expressed siRNAs have been used to target a number of early and late viral mRNAs as well as cellular cofactors (7, 27, 28) . Successful inhibition of HIV replication has been achieved in numerous human cell lines and primary cells including hematopoietic stem cell-derived T lymphocytes and macrophages (29) . The use of siRNA as a potential therapeutic agent in the treatment of HIV and hepatitis C virus (HCV) (30) (31) (32) (33) is complicated by the high mutation rates of these viruses during replication. Since even one nucleotide mismatch between an siRNA and its target can drastically lower activity (6, 34) , the appearance of escape mutants is likely. Selecting targets in highly conserved sequences (where mutations are presumably deleterious to the virus) and using combinations of si/shRNAs targeting different sites within the HIV viral genome will reduce the likelihood of resistant variants arising. The multitargeting approaches of RNAi make this method a potentially powerful therapeutic for the treatment of viral infection.
Conclusion
RNAi has rapidly gained in popularity as the method of choice for target-specific down-regulation of gene expression in eukaryotic systems. Because unwanted side effects can occur, careful attention to controls must be utilized in RNAi-mediated knockdowns. As we learn more about the mechanisms involved in this phenomenon, it may be possible to increase specificity and avoid off-targeting problems by proper design of si/shRNAs. It is clear that use of this powerful biological phenomenon will continue to expand and provide fascinating new insights into gene regulation as well as exciting therapeutic applications.
